An innovative device (Tonometer Diaton) has turned screening for glaucoma into a safe, easy procedure, performed through the eyelid and without the use of anesthetic drops.

Did you know that High Eye Pressure may lead to Glaucoma and even Blindness? BiCOM Inc., with its new Tonometer Diaton now allows to painlessly test eye pressure through the Eyelid without contact with the cornea, use of anesthesia, or risk of infection. What better month than January, Glaucoma Awareness Month, to visit your eye doctor, ask them about Tonometry, and get your eyes fully checked.

In the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total.

Statin drugs that help lower cholesterol may also be beneficial in preventing glaucoma progression according to the Wiley-Blackwell journal – Clinical & Experimental Ophthalmology.

Prof. Ehud Assia, of Tel Aviv University’s Sackler School of Medicine is, quite simply, a rock star in the field of eye surgery.

Fluctuations in eye pressure may be associated with a decreasing peripheral field of vision in patients with glaucoma, even if their eye pressure remains low overall, according to a report in the August issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

In a paper published in the journal Science, scientists from deCODE genetics and academic colleagues from the National University Hospital in Reykjavik and Uppsala University in Sweden report the discovery of two common single letter variations (SNPs) in the sequence of the human genome that appear to account for virtually all cases of a major subtype of glaucoma.

Purdue University researchers have developed new miniature devices designed to be implanted in the brain to predict and prevent epileptic seizures and a nanotech sensor for implantation in the eye to treat glaucoma.

Researchers say they have found a link between a blinding eye disease called glaucoma and Alzheimer's disease. Investigators say the connection has to do with a protein called beta amyloid.

UK scientists have shown for the first time that key proteins involved in Alzheimer's disease are also implicated in glaucoma, the major cause of irreversible blindness worldwide. Research carried out at the UCL Institute of Ophthalmology and funded by the Wellcome Trust has also shown that novel drugs being trialled for Alzheimer's disease which target this protein may be used to treat glaucoma.

Iowa State University researchers have developed a new technique that successfully treated rats for blindness caused by glaucoma. Their experimental treatment will be used on canine patients in the next year. If successful, it is expected to move to human trials.